Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intensive Chemo-immunotherapy in PTCL
NCT01679860Phase 2Completed
- Sponsor
- Fondazione IRCCS - Istituto Nazionale dei Tumori di Milano
- Start
- Nov 2006
- Primary completion
- Dec 2011
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of alemtuzumab in peripheral T-cell lymphoma (PTCL), sponsored by Fondazione IRCCS - Istituto Nazionale dei Tumori di Milano. Started Nov 2006; status: completed.
02
Drugs
alemtuzumab
03
Conditions
peripheral T-cell lymphoma (PTCL)
Beyond the preview
Go deeper on NCT01679860.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01679860.